Kiniksa Pharmaceuticals Files Form 4 on April 8, 2026
Ticker: KNSA · Form: 4 · Filed: 2026-04-08T16:34:47-04:00
Sentiment: neutral
Topics: insider-filing, ownership-change
TL;DR
Kiniksa Pharma filed a Form 4 on 4/8/26 for ownership changes on 4/6/26.
AI Summary
On April 8, 2026, Kiniksa Pharmaceuticals International, plc filed a Form 4, reporting changes in beneficial ownership of securities. The report covers transactions that occurred on April 6, 2026. Specific details regarding the nature of the transactions, the number of shares, and the individuals involved are not provided in this summary document.
Why It Matters
Form 4 filings are crucial for investors as they disclose changes in stock ownership by company insiders, providing insights into their confidence in the company's performance.
Risk Assessment
Risk Level: low — This filing is a standard disclosure of ownership changes by insiders and does not inherently indicate positive or negative company performance.
Key Players & Entities
- Kiniksa Pharmaceuticals International, plc (company) — Issuer
- 0001730430 (company) — Issuer CIK
- 0001384243-26-000008 (filing_id) — SEC Accession Number
- 2026-04-08 (date) — Filing Date
- 2026-04-06 (date) — Period of Report
FAQ
What is the SEC Accession Number for this filing?
The SEC Accession Number is 0001384243-26-000008.
What is the filing date of this Form 4?
The filing date is 2026-04-08.
What period does this report cover?
The period of report is 2026-04-06.
What is the CIK number for Kiniksa Pharmaceuticals International, plc?
The CIK number for Kiniksa Pharmaceuticals International, plc is 0001730430.
What is the primary business of Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals is in the Pharmaceutical Preparations industry (SIC 2834).
From the Filing
EDGAR Filing Documents for 0001384243-26-000008 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 4 - Statement of changes in beneficial ownership of securities: SEC Accession No. 0001384243-26-000008 Filing Date 2026-04-08 Accepted 2026-04-08 16:34:47 Documents 1 Period of Report 2026-04-06 Document Format Files Seq Description Document Type Size 1 form4-04082026_080443.html 4 1 form4-04082026_080443.xml 4 7745 Complete submission text file 0001384243-26-000008.txt 9350 Mailing Address C/O KINIKSA PHARMACEUTICALS 100 HAYDEN AVE. LEXINGTON MA 02421 Business Address Quart Barry D ( Reporting ) CIK : 0001384243 (see all company filings) Type: 4 | Act: 34 | File No.: 001-38492 | Film No.: 26848557 Mailing Address 105 PICCADILLY, SECOND FLOOR LONDON United Kingdom W1J 7NJ Business Address 105 PICCADILLY, SECOND FLOOR LONDON United Kingdom W1J 7NJ 7814319100 Kiniksa Pharmaceuticals International, plc ( Issuer ) CIK : 0001730430 (see all company filings) EIN. : 981795578 | Fiscal Year End: 1231 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)